Agency Information Collection Activities; Proposed Collection; Comment Request; Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, 16673-16676 [2019-08046]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 77 / Monday, April 22, 2019 / Notices
Prevention and the Agency for Toxic
Substances and Disease Registry.
Sherri Berger,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2019–08000 Filed 4–19–19; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2019–N–0305]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Deeming Tobacco
Products To Be Subject to the Federal
Food, Drug, and Cosmetic Act
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on the information
collection ‘‘Deeming Tobacco Products
To Be Subject to the Federal Food, Drug,
and Cosmetic Act (FD&C Act).’’
DATES: Submit either electronic or
written comments on the collection of
information by June 21, 2019.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before June 21, 2019.
The https://www.regulations.gov
electronic filing system will accept
comments until 11:59 p.m. Eastern Time
at the end of June 21, 2019. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
amozie on DSK9F9SC42PROD with NOTICES
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
VerDate Sep<11>2014
17:22 Apr 19, 2019
Jkt 247001
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2019–N–0305 for ‘‘Deeming Tobacco
Products To Be Subject to the FD&C
Act.’’ Received comments, those filed in
a timely manner (see ADDRESSES), will
be placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
16673
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Amber Sanford, Office of Operations,
Food and Drug Administration, Three
White Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–8867, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
E:\FR\FM\22APN1.SGM
22APN1
16674
Federal Register / Vol. 84, No. 77 / Monday, April 22, 2019 / Notices
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Deeming Tobacco Products To Be
Subject to the FD&C Act
OMB Control Number 0910–0768—
Extension
The Tobacco Control Act, enacted on
June 22, 2009, amended the FD&C Act
and provided FDA with the authority to
regulate tobacco products (Pub. L. 111–
31; 123 Stat. 1776). Specifically, section
101(b) of the Tobacco Control Act
amended the FD&C Act by adding
chapter IX (21 U.S.C. 387 through 387u),
which provides FDA with tools to
regulate tobacco products. Section 901
of the FD&C Act (21 U.S.C. 387a) states
that Chapter IX—Tobacco Products
applies to all cigarettes, cigarette
tobacco, roll-your-own tobacco, and
smokeless tobacco and to any other
tobacco products that the Secretary of
Health and Human Services by
regulation deems to be subject to this
chapter.
The FD&C Act provides FDA
authority to regulate cigarettes, cigarette
tobacco, roll-your-own tobacco,
smokeless tobacco, and any other
tobacco products that the Agency by
regulation deems to be subject to the
law. On May 10, 2016 (81 FR 28973)
FDA issued a final rule to deem
products meeting the statutory
definition of ‘‘tobacco product’’ to be
subject to the FD&C Act. This final rule
extended FDA’s ‘‘tobacco product’’
authorities under Chapter IX to all
tobacco products that meet the statutory
definition of ‘‘tobacco product’’ in
section 201(rr) of the FD&C Act (21
U.S.C. 321(rr)).
Section 910(a)(1) of the FD&C Act (21
U.S.C. 387j(a)(1)) defines a ‘‘new
tobacco product’’ as a tobacco product
that was not commercially marketed in
the United States on February 15, 2007,
or a modification (including a change in
design, any component, any part, or any
constituent, including a smoke
constituent, or in the content, delivery,
or form of nicotine, or any other
additive or ingredient) of a tobacco
product where the modified product
was commercially marketed in the
United States after February 15, 2007.
An order under section 910(c)(1)(A)(i) of
the FD&C Act is required prior to
marketing a new tobacco product. This
requirement applies unless the product
has been shown to be substantially
equivalent to a valid predicate product
or is exempt from substantial
equivalence.
Section 910(b) of the FD&C Act states
that a premarket tobacco application
(PMTA) shall contain full reports of all
investigations of health risks; a full
statement of all components,
ingredients, additives, and properties,
and of the principle or principles of
operation of such tobacco product; a full
description of methods of
manufacturing and processing (which
includes; a listing of all manufacturing,
packaging, and control sites for the
product); an explanation of how the
product complies with applicable
tobacco product standards; samples of
the product and its components; and
labeling.
FDA also encourages persons who
would like to study their new tobacco
product to meet with the Office of
Science in the Center for Tobacco
Products (CTP) to discuss their
investigational plan. The request for a
meeting should be sent in writing to the
Director of CTP’s Office of Science and
should include adequate information for
FDA to assess the potential utility of the
meeting and to identify FDA staff
necessary to discuss agenda items.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
Activity
Number of
responses
per
respondent
Total annual
responses
Average
burden per
response
(in hours)
Total hours
Obtaining an FDA Order Authorizing Marketing of Tobacco Product (the application) and 21 CFR 25.40 Environmental Assessments:
Other Tobacco, E-Cigarettes, and Nicotine Product Manufacturers (Electronic Nicotine Delivery Systems (ENDS)
Liquids and Delivery Systems (Including Importers)) ......
Total Hours Obtaining an FDA Order Authorizing Marketing of Tobacco Product (the application) .............
200
3.75
750
1,713
1,284,750
........................
........................
........................
........................
1,284,750
amozie on DSK9F9SC42PROD with NOTICES
Request for Meeting with CTP’s Office of Science to Discuss Investigational Plan:
Other Tobacco, E-Cigarettes, and Nicotine Product Manufacturers (Electronic Nicotine Delivery Systems (ENDS)
Liquids and Delivery Systems (Including Importers)) ......
200
1
200
4
800
Total Hours Request for Meeting with CTP’s Office of
Science to Discuss Investigational Plan ...................
........................
........................
........................
........................
800
Total Hours ‘‘Applications for Premarket Review
of New Tobacco Products‘‘ ................................
........................
........................
........................
........................
1,285,550
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
FDA estimates that it will take each
respondent approximately 1,500 hours
to prepare a PMTA seeking an order
from FDA allowing the marketing of a
VerDate Sep<11>2014
17:22 Apr 19, 2019
Jkt 247001
new tobacco product. FDA also
estimates that it would on average take
an additional 213 hours to prepare an
environmental assessment in
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
accordance with the requirements of 21
CFR 25.40, for a total of 1,713 hours per
PMTA application. This average
represents a wide range of hours that
E:\FR\FM\22APN1.SGM
22APN1
16675
Federal Register / Vol. 84, No. 77 / Monday, April 22, 2019 / Notices
will be required for these applications
under different circumstances, with a
small number requiring more hours
(e.g., as many as 5,000 hours for early
applications that involve complex
products and for which the company
has no experience conducting studies or
preparing analysis of public health
impacts, or for which reliance on master
files is not possible) as well as many
requiring fewer hours (e.g., as few as 50
hours for applications for products that
are very similar to other new products).
A PMTA may require one or more types
of studies including chemical analysis,
nonclinical studies, and clinical studies.
FDA also estimates the number of
PMTAs that FDA expects to receive
annually will be 750 (642 ENDS Liquids
and 108 ENDS Delivery Systems).
For tobacco products already on the
market at the time of the final rule,
much of the information required to
support a PMTA may be obtained from
previously published research on
similar products. Therefore, FDA
expects that a large portion of
applications may be reviewed with no
or minimal new nonclinical or clinical
studies being conducted to support an
application. In contrast, nonclinical and
clinical studies may be required for
market authorization of a new product
for which there is limited understanding
of its potential impact on the public
health. The range of hours involved to
compile these two types of applications
would be quite variable.
FDA anticipates that the 200 potential
respondents to this collection may need
to meet with CTP’s Office of Science to
discuss their investigational plans. To
request this meeting, applicants should
compile and submit information to FDA
for meeting approval. FDA estimates
that it will take approximately 4 hours
to compile this information, for a total
of 800 hours additional burden.
Therefore, the total annual burden for
submitting PMTA applications is
estimated to be 1,285,550 hours. FDA’s
estimates are based on the
corresponding information collection
estimates that apply to tobacco products
currently subject to the FD&C Act and
an assumption that manufacturers
would submit applications for the
premarket review of tobacco products.
In § 1143.3(c) (21 CFR 1143.3(c)) an
exemption is provided to the
manufacturer of a product that
otherwise would be required to include
the warning statement in § 1143.3(a)(1)
on its packages and in its
advertisements, i.e., ‘‘WARNING: This
product contains nicotine. Nicotine is
an addictive chemical.’’ This warning
will be required to appear on at least 30
percent of the two principal display
panels of the package and on at least 20
percent of the area of the advertisement.
To obtain an exemption from this
requirement, a manufacturer would be
required to certify to FDA that its
product does not contain nicotine and
that the manufacturer has data to
support that assertion. For any product
that obtains this exemption, the section
requires that the product bear the
statement: ‘‘This product is made from
tobacco.’’ The parties that package and
label such products will share
responsibility for ensuring that this
alternative statement is included on
product packages and in
advertisements. Companies are
permitted to obtain an exemption from
this warning requirement in the event
that such tobacco products are
developed in the future.
TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
responses
per
respondent
Number of
respondents
Activity
Average
burden per
response
(in hours)
Total annual
responses
Total hours
Certification Statement .........................................................
5
1
5
20
100
Total Exemptions From the Required Warning Statement Requirement .....................................................
........................
........................
........................
........................
100
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
The estimated average burden per
response is based on currently approved
information collection estimates.
Although very few certifications are
expected for tobacco products that do
not contain nicotine, FDA estimates that
the number of certification submissions
could rise if the Agency decides in the
future to address not only nicotine, but
any other addictive substances.
The estimated hours listed in the
burden table for certification
submissions reflect the time needed to
test the product for nicotine and to
prepare and submit the self-certification
request. FDA expects that these types of
certifications will be rare and estimates
that the Agency will receive on average
five submissions per year.
FDA concludes that the labeling
statements in §§ 1143.3(a)(1) and
1143.5(a)(1) and the alternative
statement in § 1143.3(c) (i.e., ‘‘This
product is made from tobacco’’) are not
subject to review by OMB because they
do not constitute a ‘‘collection of
information’’ under the PRA (44 U.S.C.
3501–3520). Rather, these labeling
statements are a ‘‘public disclosure’’ of
information originally supplied by the
Federal Government to the recipient for
the purpose of ‘‘disclosure to the
public’’ (5 CFR 1320.3(c)(2)).
TABLE 3—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
amozie on DSK9F9SC42PROD with NOTICES
Cigar warning plan
Number of
responses
per
respondent
Total annual
responses
Average
burden per
response
(in hours)
Total hours
Manufacturers, Importers, and Retailers .............................
10
1
10
120
1,200
Total Cigar Warning Plan .............................................
........................
........................
........................
........................
1,200
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
VerDate Sep<11>2014
17:22 Apr 19, 2019
Jkt 247001
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
E:\FR\FM\22APN1.SGM
22APN1
16676
Federal Register / Vol. 84, No. 77 / Monday, April 22, 2019 / Notices
The requirement for submission of
warning plans for cigar products, and
the specific requirements relating to the
random display and distribution of
required warning statements on cigar
packaging and quarterly rotation of
required warning statements in
alternating sequence on cigar product
advertising, appear in § 1143.5(c).
The six warnings for cigars (five
specifically for cigars and the one
addictiveness warning) will be required
to be randomly displayed in each 12month period, in as equal a number of
times as is possible on each brand of
cigar sold in product packaging and be
randomly distributed in all areas of the
United States in which the product is
marketed accordance with a warning
plan submitted to and approved by
FDA. For advertisements, the warning
statements must be rotated quarterly in
alternating sequence in each
advertisement for each brand of cigar in
accordance with a warning plan
submitted to and approved by FDA.
FDA published a final guidance in
August 2018 (https://www.fda.gov/
downloads/TobaccoProducts/Labeling/
RulesRegulationsGuidance/
UCM534739.pdf) to assist
manufacturers, importers, distributors,
and retailers of cigars with the
submission of warning plans. FDA will
work with the submitters to ensure that
the plans submitted meet the
established criteria for approval under
21 CFR part 1143.
The warning statements on cigar
packaging must be randomly displayed
in each 12-month period, in as equal a
number of times as is possible on each
brand of cigar sold and are required to
be randomly distributed in all areas of
the United States in which the product
is marketed in accordance with a
warning plan submitted by the
responsible cigar manufacturer,
importer, distributor, or retailer to and
approved by FDA.
FDA also requires that the required
warning statements be rotated quarterly
in alternating sequence in each
advertisement for each brand of cigar,
regardless of whether the cigar is sold in
product packaging. This rotation of
warning statements in cigar
advertisements also must be done in
accordance with a warning plan
submitted by the responsible cigar
manufacturer, importer, distributor, or
retailer to and approved by FDA.
The burden estimates are based on
FDA’s experience with cigar warning
plans, smokeless warning plans, and the
associated information collection (OMB
control number 0910–0671) as well as
warning plans for cigarettes submitted
to the Federal Trade Commission prior
to the implementation of the Tobacco
Control Act on June 22, 2009.
We estimate 10 entities will submit
warning plans, and it will take an
average of 120 hours per respondent to
prepare and submit a warning plan for
packaging and advertising for a total of
1,200 hours.
TABLE 4—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
Activity
Total annual
responses
Average
burden per
response
(in hours)
Total hours
Small-Scale Manufacturer Reporting ...................................
75
1
75
2
150
Total Small-Scale Manufacturer Report .......................
........................
........................
........................
........................
150
1 There
amozie on DSK9F9SC42PROD with NOTICES
Number of
responses
per
respondent
are no capital costs or operating and maintenance costs associated with this collection of information.
Generally, FDA considers a ‘‘smallscale tobacco product manufacturer’’ to
be a manufacturer of any regulated
tobacco product that employs 150 or
fewer full-time equivalent employees
and has annual total revenues of
$5,000,000 or less. FDA considers a
manufacturer to include each entity that
it controls, is controlled by, or is under
common control with such
manufacturer. To help make FDA’s
individual enforcement decisions more
efficient, a manufacturer may
voluntarily submit information
regarding employment and revenues.
FDA does not believe many
manufacturers who fit the criteria of a
small-scale tobacco product
manufacturer would submit the
voluntary information.
FDA estimates that there are
approximately 75 small-scale
manufacturers who will voluntarily
submit information. FDA believes it will
take respondents 2 hours to voluntarily
submit information regarding
employment and revenues for a total of
150 hours.
The total estimated burden for this
information collection is 1,286,950
VerDate Sep<11>2014
17:22 Apr 19, 2019
Jkt 247001
reporting hours, and 1,040 annual
responses. Our estimated burden for the
information collection reflects an
overall decrease of 39,050 hours and a
corresponding decrease of 315
responses. We attribute this adjustment
to updated information in the number of
submissions we received over the last
few years.
Dated: April 17, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the Circulatory System
Devices Panel of the Medical Devices
Advisory Committee. The general
function of the committee is to provide
advice and recommendations to the
Agency on FDA’s regulatory issues. The
meeting will be open to the public.
SUMMARY:
[FR Doc. 2019–08046 Filed 4–19–19; 8:45 am]
The meeting will be held on June
19, 2019, from 8 a.m. to 5 p.m., and June
20, 2019, from 8 a.m. to 3 p.m.
BILLING CODE 4164–01–P
ADDRESSES:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2019–N–1677]
Circulatory System Devices Panel of
the Medical Devices Advisory
Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
PO 00000
Notice.
Frm 00040
Fmt 4703
Sfmt 4703
DATES:
Gaithersburg Holiday Inn,
Grand Ballroom, Two Montgomery
Village Ave., Gaithersburg, MD 20879.
The hotel’s telephone number is 301–
948–8900; additional information is
available online at: https://
www.ihg.com/holidayinn/hotels/us/en/
gaithersburg/wasrv/hoteldetail?cm_
mmc=Google. Answers to commonly
asked questions including information
regarding special accommodations due
to a disability, visitor parking, and
transportation may be accessed at:
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm408555.htm.
E:\FR\FM\22APN1.SGM
22APN1
]]>Agencies
[Federal Register Volume 84, Number 77 (Monday, April 22, 2019)]
[Notices]
[Pages 16673-16676]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-08046]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2019-N-0305]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Deeming Tobacco Products To Be Subject to the Federal
Food, Drug, and Cosmetic Act
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
an opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(PRA), Federal Agencies are required to publish notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information, and
to allow 60 days for public comment in response to the notice. This
notice solicits comments on the information collection ``Deeming
Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic
Act (FD&C Act).''
DATES: Submit either electronic or written comments on the collection
of information by June 21, 2019.
ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. Electronic comments
must be submitted on or before June 21, 2019. The https://www.regulations.gov electronic filing system will accept comments until
11:59 p.m. Eastern Time at the end of June 21, 2019. Comments received
by mail/hand delivery/courier (for written/paper submissions) will be
considered timely if they are postmarked or the delivery service
acceptance receipt is on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2019-N-0305 for ``Deeming Tobacco Products To Be Subject to the
FD&C Act.'' Received comments, those filed in a timely manner (see
ADDRESSES), will be placed in the docket and, except for those
submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Amber Sanford, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A-12M, 11601
Landsdown St., North Bethesda, MD 20852, 301-796-8867,
[email protected].
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance
[[Page 16674]]
of FDA's functions, including whether the information will have
practical utility; (2) the accuracy of FDA's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Deeming Tobacco Products To Be Subject to the FD&C Act
OMB Control Number 0910-0768--Extension
The Tobacco Control Act, enacted on June 22, 2009, amended the FD&C
Act and provided FDA with the authority to regulate tobacco products
(Pub. L. 111-31; 123 Stat. 1776). Specifically, section 101(b) of the
Tobacco Control Act amended the FD&C Act by adding chapter IX (21
U.S.C. 387 through 387u), which provides FDA with tools to regulate
tobacco products. Section 901 of the FD&C Act (21 U.S.C. 387a) states
that Chapter IX--Tobacco Products applies to all cigarettes, cigarette
tobacco, roll-your-own tobacco, and smokeless tobacco and to any other
tobacco products that the Secretary of Health and Human Services by
regulation deems to be subject to this chapter.
The FD&C Act provides FDA authority to regulate cigarettes,
cigarette tobacco, roll-your-own tobacco, smokeless tobacco, and any
other tobacco products that the Agency by regulation deems to be
subject to the law. On May 10, 2016 (81 FR 28973) FDA issued a final
rule to deem products meeting the statutory definition of ``tobacco
product'' to be subject to the FD&C Act. This final rule extended FDA's
``tobacco product'' authorities under Chapter IX to all tobacco
products that meet the statutory definition of ``tobacco product'' in
section 201(rr) of the FD&C Act (21 U.S.C. 321(rr)).
Section 910(a)(1) of the FD&C Act (21 U.S.C. 387j(a)(1)) defines a
``new tobacco product'' as a tobacco product that was not commercially
marketed in the United States on February 15, 2007, or a modification
(including a change in design, any component, any part, or any
constituent, including a smoke constituent, or in the content,
delivery, or form of nicotine, or any other additive or ingredient) of
a tobacco product where the modified product was commercially marketed
in the United States after February 15, 2007. An order under section
910(c)(1)(A)(i) of the FD&C Act is required prior to marketing a new
tobacco product. This requirement applies unless the product has been
shown to be substantially equivalent to a valid predicate product or is
exempt from substantial equivalence.
Section 910(b) of the FD&C Act states that a premarket tobacco
application (PMTA) shall contain full reports of all investigations of
health risks; a full statement of all components, ingredients,
additives, and properties, and of the principle or principles of
operation of such tobacco product; a full description of methods of
manufacturing and processing (which includes; a listing of all
manufacturing, packaging, and control sites for the product); an
explanation of how the product complies with applicable tobacco product
standards; samples of the product and its components; and labeling.
FDA also encourages persons who would like to study their new
tobacco product to meet with the Office of Science in the Center for
Tobacco Products (CTP) to discuss their investigational plan. The
request for a meeting should be sent in writing to the Director of
CTP's Office of Science and should include adequate information for FDA
to assess the potential utility of the meeting and to identify FDA
staff necessary to discuss agenda items.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of Total annual burden per
Activity respondents responses per responses response (in Total hours
respondent hours)
----------------------------------------------------------------------------------------------------------------
Obtaining an FDA Order Authorizing Marketing of Tobacco Product (the application) and 21 CFR 25.40 Environmental
Assessments:
----------------------------------------------------------------------------------------------------------------
Other Tobacco, E-Cigarettes, and 200 3.75 750 1,713 1,284,750
Nicotine Product Manufacturers
(Electronic Nicotine Delivery
Systems (ENDS) Liquids and
Delivery Systems (Including
Importers))....................
Total Hours Obtaining an FDA .............. .............. .............. .............. 1,284,750
Order Authorizing Marketing
of Tobacco Product (the
application)...............
----------------------------------------------------------------------------------------------------------------
Request for Meeting with CTP's Office of Science to Discuss Investigational Plan:
----------------------------------------------------------------------------------------------------------------
Other Tobacco, E-Cigarettes, and 200 1 200 4 800
Nicotine Product Manufacturers
(Electronic Nicotine Delivery
Systems (ENDS) Liquids and
Delivery Systems (Including
Importers))....................
----------------------------------------------------------------------------------------------------------------
Total Hours Request for .............. .............. .............. .............. 800
Meeting with CTP's Office
of Science to Discuss
Investigational Plan.......
----------------------------------------------------------------------------------------------------------------
Total Hours .............. .............. .............. .............. 1,285,550
``Applications for
Premarket Review of New
Tobacco Products``.....
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
FDA estimates that it will take each respondent approximately 1,500
hours to prepare a PMTA seeking an order from FDA allowing the
marketing of a new tobacco product. FDA also estimates that it would on
average take an additional 213 hours to prepare an environmental
assessment in accordance with the requirements of 21 CFR 25.40, for a
total of 1,713 hours per PMTA application. This average represents a
wide range of hours that
[[Page 16675]]
will be required for these applications under different circumstances,
with a small number requiring more hours (e.g., as many as 5,000 hours
for early applications that involve complex products and for which the
company has no experience conducting studies or preparing analysis of
public health impacts, or for which reliance on master files is not
possible) as well as many requiring fewer hours (e.g., as few as 50
hours for applications for products that are very similar to other new
products). A PMTA may require one or more types of studies including
chemical analysis, nonclinical studies, and clinical studies. FDA also
estimates the number of PMTAs that FDA expects to receive annually will
be 750 (642 ENDS Liquids and 108 ENDS Delivery Systems).
For tobacco products already on the market at the time of the final
rule, much of the information required to support a PMTA may be
obtained from previously published research on similar products.
Therefore, FDA expects that a large portion of applications may be
reviewed with no or minimal new nonclinical or clinical studies being
conducted to support an application. In contrast, nonclinical and
clinical studies may be required for market authorization of a new
product for which there is limited understanding of its potential
impact on the public health. The range of hours involved to compile
these two types of applications would be quite variable.
FDA anticipates that the 200 potential respondents to this
collection may need to meet with CTP's Office of Science to discuss
their investigational plans. To request this meeting, applicants should
compile and submit information to FDA for meeting approval. FDA
estimates that it will take approximately 4 hours to compile this
information, for a total of 800 hours additional burden.
Therefore, the total annual burden for submitting PMTA applications
is estimated to be 1,285,550 hours. FDA's estimates are based on the
corresponding information collection estimates that apply to tobacco
products currently subject to the FD&C Act and an assumption that
manufacturers would submit applications for the premarket review of
tobacco products.
In Sec. 1143.3(c) (21 CFR 1143.3(c)) an exemption is provided to
the manufacturer of a product that otherwise would be required to
include the warning statement in Sec. 1143.3(a)(1) on its packages and
in its advertisements, i.e., ``WARNING: This product contains nicotine.
Nicotine is an addictive chemical.'' This warning will be required to
appear on at least 30 percent of the two principal display panels of
the package and on at least 20 percent of the area of the
advertisement.
To obtain an exemption from this requirement, a manufacturer would
be required to certify to FDA that its product does not contain
nicotine and that the manufacturer has data to support that assertion.
For any product that obtains this exemption, the section requires that
the product bear the statement: ``This product is made from tobacco.''
The parties that package and label such products will share
responsibility for ensuring that this alternative statement is included
on product packages and in advertisements. Companies are permitted to
obtain an exemption from this warning requirement in the event that
such tobacco products are developed in the future.
Table 2--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of Total annual burden per
Activity respondents responses per responses response (in Total hours
respondent hours)
----------------------------------------------------------------------------------------------------------------
Certification Statement......... 5 1 5 20 100
-------------------------------------------------------------------------------
Total Exemptions From the .............. .............. .............. .............. 100
Required Warning Statement
Requirement................
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
The estimated average burden per response is based on currently
approved information collection estimates. Although very few
certifications are expected for tobacco products that do not contain
nicotine, FDA estimates that the number of certification submissions
could rise if the Agency decides in the future to address not only
nicotine, but any other addictive substances.
The estimated hours listed in the burden table for certification
submissions reflect the time needed to test the product for nicotine
and to prepare and submit the self-certification request. FDA expects
that these types of certifications will be rare and estimates that the
Agency will receive on average five submissions per year.
FDA concludes that the labeling statements in Sec. Sec.
1143.3(a)(1) and 1143.5(a)(1) and the alternative statement in Sec.
1143.3(c) (i.e., ``This product is made from tobacco'') are not subject
to review by OMB because they do not constitute a ``collection of
information'' under the PRA (44 U.S.C. 3501-3520). Rather, these
labeling statements are a ``public disclosure'' of information
originally supplied by the Federal Government to the recipient for the
purpose of ``disclosure to the public'' (5 CFR 1320.3(c)(2)).
Table 3--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of Total annual burden per
Cigar warning plan respondents responses per responses response (in Total hours
respondent hours)
----------------------------------------------------------------------------------------------------------------
Manufacturers, Importers, and 10 1 10 120 1,200
Retailers......................
-------------------------------------------------------------------------------
Total Cigar Warning Plan.... .............. .............. .............. .............. 1,200
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
[[Page 16676]]
The requirement for submission of warning plans for cigar products,
and the specific requirements relating to the random display and
distribution of required warning statements on cigar packaging and
quarterly rotation of required warning statements in alternating
sequence on cigar product advertising, appear in Sec. 1143.5(c).
The six warnings for cigars (five specifically for cigars and the
one addictiveness warning) will be required to be randomly displayed in
each 12-month period, in as equal a number of times as is possible on
each brand of cigar sold in product packaging and be randomly
distributed in all areas of the United States in which the product is
marketed accordance with a warning plan submitted to and approved by
FDA. For advertisements, the warning statements must be rotated
quarterly in alternating sequence in each advertisement for each brand
of cigar in accordance with a warning plan submitted to and approved by
FDA.
FDA published a final guidance in August 2018 (https://www.fda.gov/downloads/TobaccoProducts/Labeling/RulesRegulationsGuidance/UCM534739.pdf) to assist manufacturers, importers, distributors, and
retailers of cigars with the submission of warning plans. FDA will work
with the submitters to ensure that the plans submitted meet the
established criteria for approval under 21 CFR part 1143.
The warning statements on cigar packaging must be randomly
displayed in each 12-month period, in as equal a number of times as is
possible on each brand of cigar sold and are required to be randomly
distributed in all areas of the United States in which the product is
marketed in accordance with a warning plan submitted by the responsible
cigar manufacturer, importer, distributor, or retailer to and approved
by FDA.
FDA also requires that the required warning statements be rotated
quarterly in alternating sequence in each advertisement for each brand
of cigar, regardless of whether the cigar is sold in product packaging.
This rotation of warning statements in cigar advertisements also must
be done in accordance with a warning plan submitted by the responsible
cigar manufacturer, importer, distributor, or retailer to and approved
by FDA.
The burden estimates are based on FDA's experience with cigar
warning plans, smokeless warning plans, and the associated information
collection (OMB control number 0910-0671) as well as warning plans for
cigarettes submitted to the Federal Trade Commission prior to the
implementation of the Tobacco Control Act on June 22, 2009.
We estimate 10 entities will submit warning plans, and it will take
an average of 120 hours per respondent to prepare and submit a warning
plan for packaging and advertising for a total of 1,200 hours.
Table 4--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of Total annual burden per
Activity respondents responses per responses response (in Total hours
respondent hours)
----------------------------------------------------------------------------------------------------------------
Small-Scale Manufacturer 75 1 75 2 150
Reporting......................
-------------------------------------------------------------------------------
Total Small-Scale .............. .............. .............. .............. 150
Manufacturer Report........
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Generally, FDA considers a ``small-scale tobacco product
manufacturer'' to be a manufacturer of any regulated tobacco product
that employs 150 or fewer full-time equivalent employees and has annual
total revenues of $5,000,000 or less. FDA considers a manufacturer to
include each entity that it controls, is controlled by, or is under
common control with such manufacturer. To help make FDA's individual
enforcement decisions more efficient, a manufacturer may voluntarily
submit information regarding employment and revenues. FDA does not
believe many manufacturers who fit the criteria of a small-scale
tobacco product manufacturer would submit the voluntary information.
FDA estimates that there are approximately 75 small-scale
manufacturers who will voluntarily submit information. FDA believes it
will take respondents 2 hours to voluntarily submit information
regarding employment and revenues for a total of 150 hours.
The total estimated burden for this information collection is
1,286,950 reporting hours, and 1,040 annual responses. Our estimated
burden for the information collection reflects an overall decrease of
39,050 hours and a corresponding decrease of 315 responses. We
attribute this adjustment to updated information in the number of
submissions we received over the last few years.
Dated: April 17, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-08046 Filed 4-19-19; 8:45 am]
BILLING CODE 4164-01-P
